Overview
In this report we show the analysis of a thermal denaturation-based formulation screen of then commercially available therapeutic antibody Trastuzumab, in 96 different conditions with the SUPR-DSF instrument. Along with screening the stabilising agents, confidence in the results is gained as there is consistency with both Differential Scanning Calorimetry, and the formulation used for the commercial drug Herceptin®. This screen was directly measured in a single 384-well microplate in less than 1.5 hours. This high-throughput can be leveraged further through lab automation integration to screen thousands of samples per day.
